Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 6/20 | 0.41 |
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171917 | 1.00 | PTK6 (0.41) | PTK6MAPKAPK5AURKBAURKATTK | |
| SCHEMBL22123255 | 0.89 | PTK6 (0.44) | PTK6MAPKAPK5AURKBAURKATTK | |
| SCHEMBL22139063 | 0.81 | PTK6 (0.49) | PTK6MAPKAPK5AURKBTTKLCK | |
| SCHEMBL30183522 | 0.81 | PTK6 (0.49) | PTK6MAPKAPK5AURKBTTKLCK | |
| SCHEMBL30171835 | 0.80 | PTK6 (0.48) | PTK6MAPKAPK5AURKBTTKSYK | |
| SCHEMBL22125012 | 0.80 | PTK6 (0.48) | PTK6MAPKAPK5AURKBTTKSYK | |
| SCHEMBL22123074 | 0.79 | TTK (0.45) | PTK6MAPKAPK5AURKBTTKSYK | |
| SCHEMBL22123896 | 0.78 | PTK6 (0.61) | PTK6MAPKAPK5AURKBTTKLCK | |
| SCHEMBL22139099 | 0.78 | MAPKAPK5 (0.50) | PTK6MAPKAPK5AURKBAURKATTK | |
| SCHEMBL30171560 | 0.78 | MAPKAPK5 (0.50) | PTK6MAPKAPK5AURKBAURKATTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885MAPKAPK5 728/4885AURKB 3265/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2141/4885MAPKAPK5 695/4885AURKB 3352/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | PTK6 1818/4885MAPKAPK5 516/4885AURKB 3169/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK6 2211/4885MAPKAPK5 647/4885AURKB 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.